3 Kommentare / 0 neu
13.05.2014 00:51
Bild des Benutzers nachtfalter
Kommentare: 69

Organovo ist für mich einer der interessantesten ipo der letzten Jahre! Wurde 2008 in Kalifornien gegründet und ist im Bereich 3d Drucktechnologie aktiv, jedoch im medizinischen Sektor. Diese Firma braucht aus Anlegersicht wahrscheinlich einen langen Atem, wenn sie den Durchbruch aber schaffen sollte, wird das sehr revolutionär sein. Leider gilt auch hier, grosse Chancen, grosse Risiken. Wenn Organovo sich aber nicht durchsetzt, wird diese Firma verglühen, wie eine Sternschnuppe am Nachthimmel.

20.10.2016 08:04
Bild des Benutzers Aurum
Kommentare: 500

Gestern: ONVO Announces Proposed Public Offering of Common Stock

Wer hier dabei sein will / wollte ist nun ich denke eine gute Gelegenheit.

08.09.2016 03:13
Bild des Benutzers nachtfalter
Kommentare: 69

Hier könnte es langsam interessant werden!



The Company believes that, as it penetrates the toxicology market, the ExVive Human Kidney tissue service has the potential to grow into the tens of millions in annual revenue and has $100M+ revenue potential in the future as it pursues diligent sales and marketing efforts (inside of a total addressable market of over $2B).  This kidney revenue opportunity is expected to be accretive to previous market projections for liver tissue, which are of similar magnitude.  The ExVive Human Kidney and Liver products are unique in the industry in the ability to replicate complex cell-cell interactions and key elements of native tissue architecture to enable the detection of multiple clinically-relevant modes of tissue injury and to provide the unique resolving power of a controlled human tissue microenvironment to investigate mechanism and develop solutions.

Why Organovo's Latest Publication Could Be Big NewsPublishing clinical data in a scientific journal might not usually be a big deal for most companies, but it could be for this 3D bioprinting pioneer.{C}Keith Speights(TMFFishBiz)Jul 12, 2016 at 5:15PM

Human liver tissue. Image source: Getty Images.

Hundreds of thousands of scientific articles are published in journals every year. How important are they? It depends on how groundbreaking the findings are. 

The recent publication by Organovo (NYSEMKT:ONVO) and Roche (NASDAQOTH:RHHBY) researchers in the scientific journal PLOS One is an example of a major milestone. But while the information presented wasn't surprising, the paper could be a big boon for Organovo. 


In a research article published in PLOS One on July 7, scientists from Organovo and Roche detailed how Organovo's 3D bioprinted human liver tissue was able to model drug-induced liver injury and differentiate between similar compounds with very different levels of toxicity. Those compounds were antibiotics levofloxacin and trovafloxacin. Levofloxacin is nontoxic, while trovafloxacin can lead to liver failure.

The researchers used 3D bioprinted human liver tissue to model tissue-level drug-induced liver injury. To do this, they compared the dose responses of trovafloxacin and levofloxacin. What was the verdict? The research team was able to demonstrate the toxicity of trovafloxacin at clinically relevant doses.  

None of these results were out of left field. Organovo had already presented similar findings at the Society of Toxicology's annual meeting in March. In April 2015, the company presented results from an another study where its 3D liver tissue was used to detect toxicity of diabetes drug Rezulin.

 Why it matters

At first glance, the publication from Organovo's and Roche's research doesn't seem like such a big deal. For Roche, it isn't. But for Organovo, the PLOS One paper represents another key step toward building a still relatively new market for 3D bioprinted human tissues.

It's important to understand the background of trovafloxacin. Pfizer launched the drug under the brand name Trovan in 1998. The big drugmaker expected Trovan to eventually generate annual sales of as much as $1 billion. But it wasn't to be.

Truvan was withdrawn from the market in Europe after multiple people died from liver failure after taking the drug. Since 1999, the antibiotic has only been available in the U.S. for emergency use. Rezulin's story is similar. First approved by the FDA in 1997, Rezulin was taken off the market in 2000 after being linked to deaths resulting from liver failure.

In both cases, clinical studies failed to detect the potential for liver damage with the drugs. The end results were millions (and even billions) of dollars lost -- and patient deaths.

Organovo hopes that studies like the one recently published will help drugmakers appreciate the value of 3D bioprinted tissues. Between 1990 and 2010, there were 39 drugs withdrawn from the market. Ten of those drugs caused liver damage, but the toxicity wasn't picked up in testing. Another 13 drugs caused cardiovascular problems.

Drug testing using conventional 2D cell culture models has two primary drawbacks. First, 2D models don't last long. Second, they don't replicate the complicated cell-cell interactions and environment of human tissue. Animal testing doesn't always pick up drug toxicity in humans because of species variation and other factors.

Those limitations should give 3D bioprinted human tissue a competitive advantage -- if the word gets out loud and clear. Studies like the one just published will help in Organovo's effort to make sure the right people know the story. 

What's next for Organovo

Expect Organovo to trumpet the latest findings everywhere it can. I suspect that the research will help the company in its sales efforts.

On the other hand, don't expect Organovo to turn the corner on profitability just yet. The company reported a loss of $38.6 million in fiscal year 2016. While Organovo expects a significant jump in revenue in fiscal 2017 (perhaps as high as $6 million), it won't be nearly enough to make for a positive bottom line. For now, Organovo remains a stock to consider mainly for the potential of its technology.